PATENT CLAIM ANALYSIS

Application Number: 16280356
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "278100"]

Abstract:
The present invention provides formulations that support an individual's body during routine vaccination and adaptive immune response. The individuals who can benefit from these formulations are infants, children and adults. The formulations comprise ingredients that can be administered prior to, concurrent with or subsequent to the vaccination. The formulations of the present invention preferably act by targeting enzymatic reactions an individual's various metabolic pathways, maintaining balance between oxidative stress and methylation, maintaining balance between Th1 and Th2 responses, or a combination thereof during vaccination and adaptive immune response.

Claim (Index 11):
The method of supplying supportive immunization protocols targeting epigenetic expression, enzymatic kinetics and immune system homeostasis to improve vaccine response and reduce vaccine side effects by beneficially maintaining the balance between oxidative stress and methylation, by targeting gene expression for proper enzymatic reactions involved in various metabolic pathways, thereby reducing the effects of oxidative stress through the reduction in reactive oxygen species, support of methylation, supporting trans-sulfuration and proper glutathione production and support comprising:\n collecting a preliminary biomarker sample from an individual; assessing base levels of biomarkers, via a biochemical assay, to determine an individual's pre-administration biomarker status; administering a pharmacologically acceptable amount, to an individual, of the following formulation: 1 mg -10 mg of thiamin (Vitamin B1), 0.1 mg-500 mg of riboflavin (Vitamin B2), 0.5 mg-1 g of niacin (Vitamin B3), 0.5 mg-10 mg of pantothenic acid (Vitamin B5), 0.1 mg-25 mg of pyridoxine (Vitamin B6), 5 mcg-1 mg of folate (vitamin B9), 10 mcg-5,000 mcg of cobalamin (Vitamin B12), 10 mcg-1,000 mcg of Vitamin A, 50 IU-1,000 IU of Vitamin D, 1 mg-20 mg of Vitamin E, 5 mg-5,000 mg of Vitamin C, 0.5 mcg-300 mcg, of Vitamin K, 50 mg-800 mg of Calcium, 20 mcg-15 mg of Iodine, 5 mg-200 mg of Magnesium, 1 mg-15 mg of Zinc, 5 mcg-200 meg of Selenium, 0.1 mg-5 mg of Manganese, 1 mcg-150 mcg of chromium, 1 mcg-100 mcg of molybdenum, 10 mg-1 g of trimethylglycine (betaine), 10 mg-1 g of choline, 50 mg-2 g of acetyl-L-carnitine, 20 mg-500 mg of N-acetyl cysteine, 50 mg-800 mg, of milk thistle and 20 mg-800 mg of creatinine or a combination thereof; administering said formulation prior to the administration of a vaccine, concurrent with the administration of a vaccine or subsequent to the administration of a vaccine; and measuring, by a biochemical assay, the subsequent levels of biomarkers.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 99.0
- Lexical Diversity: 1.57143
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15226415', '14662143', '12080189', '12157077', '11943176']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7153041630783074
- 35 USC 102 Novelty (BERT): 0.5466595622414908
- Combined Prediction Score: 0.6984397029946257
- Mean Citation Score: 254.194662
- Max Citation Score: 440.54672
- Similarity Product: 255.33598447128296

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test